Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD

Chest

Volumn 130, Issue 3, 2006, Pages 647-656

  O'Donnell, Denis E ^a,f   Sciurba, Frank ^b   Celli, Bartolome ^c   Mahler, Donald A ^d   Webb, Katherine A ^a   Kalberg, Chris J ^e   Knobil, Katharine ^e  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

^f NONE   (Canada)

Author keywords

COPD; Exercise; Fluticasone propionate; Inhaled corticosteroid; Long acting 2 agonist; Lung hyperinflation; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEUKOTRIENE RECEPTOR AFFECTING AGENT; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDURANCE; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; LUNG MINUTE VOLUME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TIDAL VOLUME; UNSPECIFIED SIDE EFFECT;

EID: 33748848116     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.3.647     Document Type: Article

References (41)

1. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946
2. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:770-777
3. Dykstra BJ, Scanlon PD, Kester MM, et al. Lung volumes in 4,774 patients with obstructive lung disease. Chest 1999; 115:68-74
4. Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 2000; 16:269-275
5. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:967-975
6. Martinez FJ, de Oca MM, Whyte RI, et al. Lung volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155:1984-1990
7. O'Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997; 155:109-115
8. Rennard S, Decramer M, Calverley PMA, et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002; 20:799-805
9. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163:1256-1276
10. Ayers ML, Mejia R, Ward J, et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001; 17:1132-1137
11. Man WDC, Mustfa N, Nikoletou D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004; 59:471-476
12. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:542-549
13. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832-840
14. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24:86-94
15. Ramirez-Venegas A, Ward J, Lentine T, et al. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997; 112:336-340
16. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over eight hours with once-daily tiotropium in patients with COPD. Chest 2005; 128:1168-1178
17. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1557-1565
18. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843
19. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:1084-1091
20. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456
21. American Thoracic Society. Standards for the diagnosis and care of subjects with chronic obstructive pulmonary disease (COPD). Am Rev Respir Dis 1995; 152:577-5120
22. American Thoracic Society/American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277
23. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152:1107-1136
24. Blonshine S, Foss C, Mottram C, et al. AARC clinical practice guideline: body plethysmography. Respir Care 2001; 46:506-513
25. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meets ATS recommendations. Am Rev Respir Dis 1981; 123:659-664
26. Crapo RO, Morris AH, Clayton PD, et al. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopath Respir 1982; 18:419-425
27. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiological correlates of two new clinical indexes. Chest 1984; 85:751-758
28. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377-381
29. Celli B, ZuWallack RM, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124:1743-1748
30. Ayers SM, Griesbach SJ, Reimold F, et al. Bronchial component in chronic obstructive lung disease. Am J Med 1974; 57:183-191
31. Pare PD, Lawson LM, Brooks LA. Patterns of response to inhaled bronchodilators in asthmatics. Am Rev Respir Dis 1983; 127:680-685
32. Sciurba FC. Physiologic similarities and differences between COPD and asthma. Chest 2004; 126(Suppl):117S-124S
33. Johnson M. Pharmacology of long-acting β-agonists. Ann Allergy Asthma Immunol 1995; 75:177-179
34. Can WQ, Man SFP, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5:3
35. Llewellyn-Jones CG, Harris TA, Stockely RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996; 153:616-621
36. 2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268:41-46
37. 2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997; 155:704-710
38. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172:704-712
39. 2-agonists and corticosteroids on tumor necrosis factor-α-induced interleukin-8 release from cultured human airway smooth-muscle cells. Am J Respir Cell Mol Biol 2000; 23:79-85
40. Mahler DA, Fierro-Carrion G, Mejia-Alfaro R, et al. Responsiveness of continuous ratings of dyspnea during exercise in patients with COPD. Med Sci Sports Exerc 2005; 37:529-535
41. Oga T, Nishimura K, Tsukino M, et al. The effects of oritropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease: a comparison of three different exercise tests. Am J Respir Crit Care Med 2000; 161:1897-1901